Advanced Magnetics seeks US trials for agent:
This article was originally published in Clinica
Advanced Magnetics has filed an application with the FDA to begin Phase I clinical trials in the US of its new MRI contrast agent, under an investigational drug exemption. The agent, currently known as Code 7228, will be evaluated in magnetic resonance angiography for the detection of blood flow in the heart muscle and as a next-generation lymph node agent. The Cambridge, Massachusetts-based company said the product was a potential competitor to Epix Medical's MS-325 MRA contrast agent and Nycomed Amersham's NC100150 MRI contrast agent.
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.